Troutman Pepper Locke Advises Eupraxia Pharmaceuticals on $80 Million Public Offering of Common Shares

BOSTON – Troutman Pepper Locke advised Eupraxia Pharmaceuticals, Inc. (Eupraxia) (NASDAQ: EPRX; TSX: EPRX), a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug, in its public offering of 14,636,363 common shares at $5.50 per common share for gross proceeds of approximately $80.5 million, before deducting the underwriting commissions and estimated expenses incurred in connection with the offering. For more information, see the press release.

Eupraxia intends to use the net proceeds from the offering primarily for the continued advancement of its product pipeline, including the completion of ongoing preclinical studies and clinical trials, regulatory submissions, and associated commercial preparation and manufacturing scale-up activities.

The Troutman Pepper Locke team that advised Eupraxia was led by Tom Rose, Shona Smith, Nicole Edmonds, Alex Yarbrough, Jason Langford, Taylor Williams, and Joe Cataldo, and included Mark Goldsmith, Noreen Onimus, Heather Morehouse Ettinger, and Judy O’Grady.

Consistently recognized as a top-tier practice, Troutman Pepper Locke’s corporate attorneys regularly handle strategic deals for clients ranging from industry leading, Fortune 100 corporations to emerging companies. Core areas of service include mergers and acquisitions, corporate finance, corporate governance, securities laws compliance, capital markets transactions, and other significant domestic and cross-border transactions, as well as general corporate counseling.

Troutman Pepper Locke

Troutman Pepper Locke helps clients solve complex legal challenges and achieve their business goals in an ever-changing global economy. With more than 1,600 attorneys in 30+ offices, the firm serves clients in all major industry sectors, with particular depth in energy, financial services, health care and life sciences, insurance and reinsurance, private equity, and real estate. Learn more at troutman.com.